Holen Sie sich die Stockscreener-App
3.56
10.18%
0.27
Quantum Biopharma Ltd Aktie (QNTM) Neueste Nachrichten
Quantum BioPharma receives FDA clearance for MS phase 2 trial - Investing.com
A multiple sclerosis drug candidate aimed at repairing nerve coating can now begin human testing - Stock Titan
Quantum Biopharma amends Form 6-K to add exhibit to F-3 registration statement - Bitget
Quantum Biopharma (QNTM) folds April 2 press release into shelf filing - Stock Titan
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach - Almaguin News
Why Did Quantum BioPharma (CN:TCM) Stock Surge 6.846% on 4 September 2026? - kalkine.ca
Quantum BioPharma engages FinnCom for investor awareness - scanx.trade
FDA Clears Quantum BioPharma’s Lucid-MS Phase 2 Trial — Could QNTM Be Entering a Pivotal Clinical Chapter? - kalkine.ca
Quantum BioPharma settles CAD$123,487 debt via Class B shares - scanx.trade
Quantum BioPharma Ltd. (NASDAQ: QNTM) Share Price, QNTM Stock News, QNTM Share Price & Updates - kalkine.ca
Quantum BioPharma Stock Slides 5.75%: Is Clinical Execution Risk Weighing on QNTM Sentiment? - kalkine.ca
Quantum BioPharma Stock Slides 5.75% as CN:QNTM Delisting Plans Add Fresh Pressure to QNTM Sentiment - kalkine.ca
Giving up one stock exchange but not Nasdaq, Quantum BioPharma (NASDAQ: QNTM) reshapes where its shares trade - Stock Titan
Quantum BioPharma to Delist Class B Shares from Canadian Securities Exchange - marketscreener.com
Quantum BioPharma Ltd. Applies for Voluntary Delisting of Class B Shares from Canadian Securities Exchange - quiverquant.com
Quantum BioPharma to Voluntarily Delist Class B Shares from CSE, Consolidating Trading on Nasdaq - kalkine.ca
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange - Yahoo Finance
QNTM Initiated Coverage by Rodman & Renshaw -- Price Target Set at $8.00 - GuruFocus
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential - TradingView
Quantum BioPharma stock initiated with buy rating at Rodman & Renshaw - Investing.com Nigeria
Quantum BioPharma Ltd. (CN:QNTM) Rises 3.07% as FDA-Cleared Lucid-MS Program Strengthens Investor Optimism - kalkine.ca
QNTM Stock Analysis: Price-to-Sales Signals Market Skepticism De - GuruFocus
Quantum BioPharma Shares Slip 4.44% as Clinical Risk and Biotech Volatility Temper Sentiment - kalkine.ca
Headline: Quantum BioPharma Stock Under Pressure After August 25 Decline — Can Lucid-MS Catalyze a Recovery? - kalkine.ca
Quantum BioPharma Falls 4.26% After FDA Clearance Rally: Profit-Taking or a Deeper Signal? - kalkine.ca
Quantum Biopharma Provides Corporate Update - The Manila Times
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves - TradingView
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm - Benzinga
Quantum BioPharma Stock Gains 6.7% on FDA Clearance for Lucid-MS Phase 2 Trial - kalkine.ca
Quantum BioPharma Stock Under Pressure as Regulatory Uncertainty Tests the Lucid-MS Growth Story - kalkine.ca
Quantum BioPharma Stock Slides as Bearish Momentum, Funding Risk and Biotech Volatility Pressure CN:QNTM - kalkine.ca
Quantum (QNTM) Results Breakdown: The Latest Report Adds New Financial Reference Points under the Current Snapshot; Post-Earnings Trading: The Stock Records a 9.24% Decrease on the DayGuidance Revision Trend - vinanet.vn
Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - NewMediaWire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - Benzinga
Quantum BioPharma Ltd (CN:QNTM) Gains Momentum as Clinical Breakthroughs Improve Investor Outlook - kalkine.ca
Quantum BioPharma Ltd Stock Intrinsic Values | HAM:0K91 - GuruFocus
Quantum BioPharma Ltd Stock Historical Valuations - GuruFocus
QNTM Q4 2025 Earnings: Loss of $0.71 Per Share Reported as Stock Advances 17.65%Revenue Report - Vinanet
Quantum BioPharma Ltd (HAM:0K91) Stock Earnings Transcripts - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price, Trades & News - GuruFocus
Who's Buying or Selling Quantum BioPharma Ltd (HAM:0K91) Stock Today? - GuruFocus
Quantum BioPharma (HAM:0K91) ROC (Joel Greenblatt) % : -34,873.53% (As of Mar. 2026) - GuruFocus
HAM:0K91 Dividend: Does Quantum BioPharma Ltd Pay a Dividend? - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price & 30 Year Financial Data - GuruFocus
Quantum BioPharma Ltd Stock Operating Data - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Competitors 2026 - GuruFocus
Quantum BioPharma Ltd (HAM:0K91)Valuation Measures & Financial Statistics - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Valuation - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock News, Headlines & Updates - GuruFocus
Quantum BioPharma (HAM:0K91) EPS (Basic) : €-7.12 (TTM As of Mar. 2026) - GuruFocus
Quantum BioPharma (HAM:0K91) Dividend Yield % : 0.00% (As of Aug. 16, 2026) - GuruFocus
Quantum BioPharma (HAM:0K91) OCF Yield % : -22.72 (As of Aug. 16, 2026) - GuruFocus
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time - kalkine.ca
QNTM Surges 10.5%: Quantum Biopharma Gains Momentum as It Approaches Key ResistanceIV Crush Alert - Vinanet
Quantum BioPharma Stock Surges as Lucid-MS Progress and Biotech Catalysts Fuel Bullish Momentum - kalkine.ca
Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment - kalkine.ca
Quantum BioPharma Stock Faces Fresh Pressure as Biotech Risk and Funding Concerns Weigh on Sentiment - kalkine.ca
Quantum BioPharma reports Q2 results, FDA clears MS trial By Investing.com - Investing.com Nigeria
Quantum BioPharma reports Q2 results, FDA clears MS trial - Investing.com
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):